Vaginal Estrogen Treatment and Effect on Hemostatic Parameters in Postmenopausal Women
Recruiting
Phase 4
Interventional Study
Vagina Atrophy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 50 and older
- Sex
- Female
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 90 (estimated)
- Sponsor
- University of Aarhus · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study investigates whether vaginal estrogen treatment has an effect on hemostatic parameters in postmenopausal women. Blood samples are collected before and after 3 months treatment to assess changes in hemostasis.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Postmenopausal women aged ≥ 50
* Symptomatic vaginal atrophy
* Indication for standard treatment with vaginal estrogen tablets 10 µg at least three times a week
* Study population 1: without a history of venous thromboembolic event
* Study population 2: with a history of venou…
Contacts